Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps
This article was originally published in The Pink Sheet Daily
Executive Summary
In Part I of a series, panelists discuss outcomes measures in a sector with unique regulatory conditions and the need for biomarkers.
You may also be interested in...
Start-Up Archer Preps Alzheimer’s Drugs For Phase I
IND filed, company aims to use nilvadipine derivative against soluble amyloid.
Start-Up Archer Preps Alzheimer’s Drugs For Phase I
IND filed, company aims to use nilvadipine derivative against soluble amyloid.
PSA: What We Have Here Is A Failure to Innovate
Discussion at FDC/Windhover's annual Pharmaceutical Strategic Alliances gathering in New York reflected the urgent need for the industry to adopt new models in order to spur innovation--in R&D, finance, business development, and commercial operations.